Skip to main content

Development of a novel replication-deficient mucosal rna vaccine protecting against respiratory viral disease of early childhood

Objective

The aim of the project is the development and the pre-clinical evaluation of a mucosal RNA-based virosomal vaccine against respiratory diseases of the early childhood caused by human parainfluenzavirus type 3 and respiratory syncytial virus. Antigens are encoded on a Sendai virus RNA packaged in a nucleocapsid and encapsulated into immunostimulating reconstituted virosomes. For an excellent safety standard, the nucleocapsid is completely replication-deficient by deletion of the N gene. Antigen combinations are provided by a single vaccine formulation in a modular system. The vaccine will be applied in a one step process and the administration as a nasal spray allows an easy reapplication. This makes the new formulation economic, effective, safe and highly adaptable for vaccination of humans (also of animals) against various infectious diseases.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Address
Am Klopferspitz 18 A
82152 Planegg / Krailling
Germany

Participants (3)

BERNA BIOTECH LTD
Switzerland
Address
Rehhagstrasse 79 A
3018 Bern
NATIONAL UNIVERSITY OF IRELAND - MAYNOOTH
Ireland
Address

47 Maynooth - Co. Kildare
UNIVERSIT DEGLI STUDI DI SIENA
Italy
Address
Via Bracci, 16
53100 Siena